Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

前立腺肥大症(BPH)治療薬の世界市場2017-2021

◆タイトル:Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021
◆商品コード:IRTNTR13127
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年5月10日
◆ページ数:70
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、前立腺肥大症(BPH)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、前立腺肥大症(BPH)治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

ABSTRACTAbout Benign Prostatic Hyperplasia Drugs

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

Technavio’s analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi

[Other prominent vendors]
• ADC Therapeutics
• Advaxis
• Agennix
• ANI Pharmaceuticals
• Bayer HealthCare
• BHR Pharma
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Dendreon (Valeant Pharmaceuticals)
• Eisai
• Endo Pharmaceuticals
• Ferring
• Foresee Pharmaceuticals
• Io Therapeutics
• LIDDS
• Madrigal Pharmaceuticals
• Merck
• Novartis
• Nymox Pharmaceutical
• Spectrum Pharmaceuticals
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Urologix

[Market driver]
• Growing geriatric male population.
• For a full, detailed list, view our report

[Market challenge]
• Availability of minimally invasive surgery as a drug replacement.
• For a full, detailed list, view our report

[Market trend]
• Advancements in early-stage diagnosis through new diagnostic methods.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: BPH diagnostics
• Overview

PART 06: Pipeline landscape

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by MOA
• Alpha-blockers
• 5-ARIs
• PDE-5 inhibitors
• Others

PART 09: Geographical segmentation
• BPH drugs market in Americas
• BPH drugs market in EMEA
• BPH drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Advancements in early-stage diagnosis through new diagnostic methods
• Growing demand for MRI and ultrasound-guided prostate biopsy procedures
• Growing focus toward new MOA

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Risk factors of prostate gland enlargement
Exhibit 02: Difference between prostate cancer and BPH
Exhibit 03: Pipeline analysis
Exhibit 04: Pipeline landscape
Exhibit 05: Global BPH drugs market snapshot
Exhibit 06: Global BPH drugs market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by MOA 2016
Exhibit 09: Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
Exhibit 10: Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
Exhibit 11: Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
Exhibit 13: Global BPH drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: BPH drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: BPH drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: BPH drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Percentage of potential population for BPH among people with 65+ years 2014 and 2050
Exhibit 21: Prominent side effects of BPH medication
Exhibit 22: Impact of patent loss on AVODART 2014-2015 (GBP millions)
Exhibit 23: New advancements in diagnosis of BPH
Exhibit 24: Competitive structure analysis of global BPH drugs market 2016
Exhibit 25: Competitive analysis of global BPH drugs market
Exhibit 26: Astellas Pharma: Strength assessment
Exhibit 27: Astellas Pharma: Strategy assessment
Exhibit 28: Astellas Pharma: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Sanofi: Key highlights
Exhibit 37: Sanofi: Strength assessment
Exhibit 38: Sanofi: Strategy assessment
Exhibit 39: Sanofi: Opportunity assessment



【掲載企業】

Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Advaxis, Agennix, ANI Pharmaceuticals, Bayer HealthCare, BHR Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Dendreo (Valeant Pharmaceuticals), Eisai, Endo Pharmaceuticals, Ferring, Foresee Pharmaceuticals, Io Therapeutics, LIDDS, Madrigal Pharmaceuticals, Merck, Novartis, Nymox Pharmaceutical, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, and Urologix.

【資料のキーワード】

前立腺肥大症、前立腺肥大症治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[前立腺肥大症(BPH)治療薬の世界市場2017-2021] (Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021 / IRTNTR13127)販売に関する免責事項
[前立腺肥大症(BPH)治療薬の世界市場2017-2021] (Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021 / IRTNTR13127)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆